Search
brigatinib (Alunbrig)
Indications:
- metastatic ALK-positive non-small cell lung cancer (NSCLC) with progression during or after treatment with crizotinib or are intolerant to crizotinib [1,2]
- may be useful as initial therapy for ALK-positive NSCLC
Dosage:
- start 90 mg PO QD
- increase to 180 mg PO QD after 1 week if tolerated
- continue until disease progression or unacceptable toxicity
Tabs: 90 mg, 180 mg
Adverse effects:
- most common
- nausea, diarrhea, fatigue, cough, headache
- most common serious adverse events
- pneumonia, interstitial lung disease
- incidence of fatal adverse events is 3.7%
Mechanism of action:
- inhibits anaplastic lymphoma kinase & EGF receptor [3]
Interactions
drug adverse effects of tyrosine kinase inhibitor(s)
General
small inhibitory antineoplastic agent (ib drug)
tyrosine kinase inhibitor
Database Correlations
PUBCHEM cid=68165256
References
- Bankhead C
FDA Approves ALK-Targeted Drug for NSCLC -
Brigatinib for disease that progressed on crizotinib.
MedPage Today. April 28, 2017
https://www.medpagetoday.com/PublicHealthPolicy/FDAGeneral/64923
- Windle ML.
FDA New Drug and Biologic Approvals -- 2017 Year-in-Review
Medscape - Jan 11, 2018.
https://reference.medscape.com/viewarticle/890871
- U.S. Food and Drug Administration.
Novel Drug Approvals for 2017.
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
- Food & Drug Administration. April 28, 2017
Brigatinib
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555841.htm
- PubChem: 68165256
- Kim DW, Tiseo M, Ahn MJ et al
Brigatinib in Patients With Crizotinib-Refractory Anaplastic
Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer:
A Randomized, Multicenter Phase II Trial.
J Clin Oncol. 2017 Aug 1;35(22):2490-2498. Epub 2017 May 5.
PMID: 28475456
- Camidge DR, Kim HR, Ahn MJ et al
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell
Lung Cancer.
N Engl J Med 2018; 379:2027-2039. Nov 22, 2018.
PMID: 30280657
https://www.nejm.org/doi/full/10.1056/NEJMoa1810171